Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Senapati J, et al. Among authors: pierce s. Blood. 2023 Nov 9;142(19):1647-1657. doi: 10.1182/blood.2023020649. Blood. 2023. PMID: 37441846
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. Estey EH, et al. Among authors: pierce sa. Blood. 2001 Dec 15;98(13):3575-83. doi: 10.1182/blood.v98.13.3575. Blood. 2001. PMID: 11739159 Free article. Clinical Trial.
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Estey EH, et al. Blood. 2002 Jun 15;99(12):4343-9. doi: 10.1182/blood.v99.12.4343. Blood. 2002. PMID: 12036860 Free article. Clinical Trial.
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. Weiser MA, et al. Cancer. 2004 Mar 15;100(6):1179-85. doi: 10.1002/cncr.20071. Cancer. 2004. PMID: 15022284 Free article.
1,367 results